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A B S T R A C T
Background
Consistent with observational studies, a randomized controlled intervention trial of adult
male circumcision (MC) conducted in the general population in Orange Farm (OF) (Gauteng
Province, South Africa) demonstrated a protective effect against HIV acquisition of 60%. The
objective of this study is to present the first cost-effectiveness analysis of the use of MC as an
intervention to reduce the spread of HIV in sub-Saharan Africa.
Methods and Findings
Cost-effectiveness was modeled for 1,000 MCs done within a general adult male population.
Intervention costs included performing MC and treatment of adverse events. HIV prevalence
was estimated from published estimates and incidence among susceptible subjects calculated
assuming a steady-state epidemic. Effectiveness was defined as the number of HIV infections
averted (HIA), which was estimated by dynamically projecting over 20 years the reduction in
HIV incidence observed in the OF trial, including secondary transmission to women. Net savings
were calculated with adjustment for the averted lifetime duration cost of HIV treatment.
Sensitivity analyses examined the effects of input uncertainty and program coverage. All results
were discounted to the present at 3% per year.
For Gauteng Province, assuming full coverage of the MC intervention, with a 2005 adult male
prevalence of 25.6%, 1,000 circumcisions would avert an estimated 308 (80% CI 189–428)
infections over 20 years. The cost is $181 (80% CI $117–$306) per HIA, and net savings are $2.4
million (80% CI $1.3 million to $3.6 million). Cost-effectiveness is sensitive to the costs of MC
and of averted HIV treatment, the protective effect of MC, and HIV prevalence. With an HIV
prevalence of 8.4%, the cost per HIA is $551 (80% CI $344–$1,071) and net savings are $753,000
(80% CI $0.3 million to $1.2 million). Cost-effectiveness improves by less than 10% when MC
intervention coverage is 50% of full coverage.
Conclusions
In settings in sub-Saharan Africa with high or moderate HIV prevalence among the general
population, adult MC is likely to be a cost-effective HIV prevention strategy, even when it has a
low coverage. MC generates large net savings after adjustment for averted HIV medical costs.
The Editors’ Summary of this article follows the references.
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Introduction
Despite hopeful signs of abatement in a few countries, the
HIV epidemic continues to spread [1]. In the face of this
challenge, substantial new resources have been committed to
expand access to both prevention and treatment. These
include the United States’ Emergency Plan for AIDS Relief,
the World Bank’s Multi Country AIDS Projects, the World
Health Organization’s 3 by 5 Initiative, and the Global Fund
to Fight AIDS, Tuberculosis and Malaria [2–4]. As the
financial and political commitment to prevention intensifies,
so too does the sense of urgency to identify new and effective
methods to reduce transmission. The geographical area with
the highest numbers of infected persons is sub-Saharan
Africa [5]. Success in this setting remains critical to stemming
the global epidemic.
Most prevention strategies among adults in sub-Saharan
Africa focus on altering key HIV risk behaviors and treatment
of sexually transmitted infections (STIs), but often lack
confirmatory evidence of reduced HIV incidence. The most
effective interventions, such as sex worker programs, apply
only to limited groups [6,7]. Effective vaccines remain elusive
and are unlikely to be ready for many years [8,9]. Thus, new
biologically based interventions that provide partial but
durable protection not dependent on sustained behavioral
change could make a significant contribution.
Observational studies have repeatedly shown that male
circumcision (MC) offers substantial protection. A meta-
analysis of 27 observation studies of MC in sub-Saharan
Africa found that 21 showed evidence of reduced risk of
infection (crude relative risk [RR] ¼ 0.52; 95% confidence
interval [CI] 0.40–0.68). In the subset of 15 studies that
adjusted for potential confounding variables, circumcision
appeared to reduce risk by over half (adjusted RR¼0.42; 95%
CI 0.34–0.54) [10]. Ecological studies have shown that
countries where males are circumcised, and generally at an
early age, are less affected than others by the HIV epidemic.
These studies argue for the likelihood of a durable protective
effect [11]. The protective effect of MC is biologically
plausible [12].
Recently, the first randomized clinical trial of MC,
conducted in Orange Farm (OF), South Africa, provided the
first experimental evidence. This trial found a risk reduction
similar to that in meta-analyses (RR¼ 0.40; CI 0.24–0.68) [13].
Two additional randomized, controlled trials (RCTs) are
underway, in Kenya and Uganda, and will be completed by
2007.
In addition to high efficacy, MC is a one-time medical
intervention with partial but likely durable effect, potentially
applicable to all uncircumcised men. In populations with
null or low existing circumcision rates, the scope of public
health benefit is potentially high [14]. MC in adults and
children may be a key part of a broadened program of HIV
prevention in the next years. There is already some adult
male circumcision in this region; a 2002 Human Sciences
Research Council study found that 35% of South African
adults and young males have been circumcised, at a mean
age of 15 years [15].
While funds for prevention have greatly increased in recent
years, they still fall far short of what is needed [16–18]. It is
thus appropriate to consider how MC compares with other
prevention and treatment strategies in developing countries
in terms of economic criteria. Recent reviews of HIV
prevention cost-effectiveness suggest a range of $10 to more
than $10,000 per HIV infection averted (HIA) [19,20].
South African studies on the cost-effectiveness of HIV
interventions focus on mother-to-child transmission preven-
tion interventions (with results ranging from cost saving if
adjusted for averted medical care cost to $2,492 per HIA) [21–
24] and the cost-effectiveness of ongoing antiretroviral
therapy [25–27]. Provision of the female condom to sex
workers was found to be cost saving if adjusted for averted
medical care costs [28]. A study of rescreening for HIV during
late pregnancy found net savings [29], and another study
found that targeted STI treatment in sex workers costs $78
per disability-adjusted life year (DALY) [30]. Other studies did
not use the outcome metric of costs per HIA or per life year
saved [21,29–32]. No studies have been carried out on the
cost-effectiveness of MC, a requirement before wide adoption
should be undertaken [33].
The purpose of this analysis is (1) to assess the cost-
effectiveness of MC for Gauteng Province, South Africa,
where the randomized controlled trial took place, allowing
comparison with other prevention strategies, and (2) using
the analytic framework thus established, to estimate cost-
effectiveness in sub-Saharan African settings with slightly
different epidemiology or cost structure.
Methods
Overview
We estimated cost-effectiveness for a hypothetical cohort
of 1,000 newly circumcised South African adult men in the
general population. Base case values for inputs derived from
the RCT in OF and, when not measured in the OF trial, from
other studies or estimates [13]. Costs included performing the
circumcisions, providing community publicity, and treating
adverse events. Effectiveness, defined as number of HIA
among adults, was calculated by projecting the reduction in
HIV incidence observed in the RCT over 20 years, adjusted
for epidemic effects that would alter benefits. Cost-effective-
ness was calculated with and without adjustment for the
averted lifetime cost of HIV treatment, with explicit
assumptions about use of antiretroviral treatment (ART).
We estimated the change in DALYs, a measure of the burden
of disease. We performed sensitivity analyses for individual
inputs, program coverage, and different geographic settings
in sub-Saharan Africa.
Model
We developed a deterministic cost and epidemiologic
model using a computer spreadsheet (available on request
from the authors). This model calculates the program cost of
the intervention as the sum of the number of MC performed
times the unit cost of MC, an estimated cost for publicity, and
the frequency of adverse events times their unit costs. The
adjusted cost subtracts the savings in medical costs due to
averted HIV infections. The expected benefit of MC (HIV
infections prevented) is calculated on the basis of the
estimated HIV incidence in susceptible men and the
reduction in that incidence due to MC. A linked epidemic
model calculates indirect protection of women through lower
HIV prevalence in men. The model assumes no direct benefit
to the female partners of circumcised men since limited
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observational data suggest little or no protection of these
partners [34,35]. The model also does not account for the
impact on children that the indirect benefit to females would
have.
We calculated the unadjusted program cost per HIA, for
comparability with prior analyses. Since adjusted costs (i.e.,
reflecting averted HIV medical costs) were negative, we
report net savings for the cohort. We also estimated the net
reduction in DALYs accounting for HIV infections prevented
and adverse events. We did not calculate the reference cost-
effectiveness ratio (i.e., using a quality adjusted measure of
life years in the denominator); with a negative numerator,
this ratio is difficult to interpret and counter-intuitive in its
response to changes in numerator or denominator [36].
Detail on key model features is provided below and in the
Protocol S1.
Specific cost inputs are the observed cost (including
publicity) per MC during the OF RCT, the cost of adverse
events, and the lifetime cost of treating HIV/AIDS cases.
Specific epidemiologic parameters include the proportion of
susceptible persons (HIV-negative) in the population, HIV
incidence rate, protective benefit of MC for males, increased
risk due to risk compensation, and adjustment of HIV
infections prevented due to epidemic dynamics. Input
estimates were derived from the OF trial data and assigned
ranges based on CIs established by the trial. For inputs not
derivable from this trial, low and high values were chosen to
encompass likely ranges.
The analysis adopts the perspective of a government health
care payer in South Africa. Costs are for 2006, and future
costs and benefits are discounted to 2006 at 3% annually, the
rate recommended by the Panel on Cost-Effectiveness in
Health and Medicine of the US Public Health Service and
other analysts [36,37].
We conducted sensitivity analyses to assess the effect of
uncertainty in input values. We used one-way sensitivity
analyses for all inputs and report them for the six inputs that
had the largest effects on results or for which the small effects
were important to document. We used three-way sensitivity
analysis to explore the combined effect of varying MC cost,
protective effect, and an ‘‘epidemic multiplier’’ (described in
‘‘Effectiveness,’’ below). We conducted threshold analyses for
these two inputs for $0 net cost and for risk compensation
(i.e., increased risky sexual behavior) for stable HIV incidence
(no HIA). We also performed multivariate Monte Carlo
simulations, which estimate the aggregate uncertainty from
all inputs (Crystal Ball, version 7.2, Decisioneering [http://
www.decisioneering.com]). In a 100,000-trial simulation, all
model inputs were varied simultaneously. Input parameters
were assigned values using symmetrical beta distributions
with the base case as the mean and the tails bounded by the
ranges shown in Table 1. This allowed us to determine 95%
and 80% CIs. (For simplicity, the interval between the tenth
and 90th, and 2.5th and 97.5th, percentiles are referred to as
the 80% or 95% CIs, respectively.) We repeated the base case
Monte Carlo with a symmetrical uniform distribution.
Finally, we examined three scenarios representing different
epidemic settings, client characteristics, and coverage or
uptake (i.e., number of MC, divided by the number of
previously uncircumcised sexually active men in the com-
munity).
Client Population
This analysis assumes a cohort of 1,000 adult males (older
than 18 years) in the general population. This group is older
than the relatively young subjects in the OF trial (aged 18–24)
and thus has a higher HIV prevalence (see Discussion). In the
base case we assume full MC program coverage. Other client
scenarios examined include lower HIV prevalence and
incidence, a focus on younger men (either initially or after
circumcising all adult men), and lower MC program coverage.
Costs
We considered all direct program and medical costs. The
cost of performing an MC during the OF RCT was $47 (350
Rand, exchange rate 7.44 mid-2003), which was the average
price charged by general practitioners in Gauteng Province
for MC performed in their offices. This fee presumably
includes all costs reasonably associated with providing the
procedure (i.e., staff salaries, supplies, space, other practice
costs). Training was not required due to familiarity with MC;
two short meetings were used to standardize the procedure,
and we assume no training cost. This cost is consistent with
values reported from MC studies in Kenya that range from
$13 to $77 [38]. We inflated the cost from mid-2003 to early
2006 using the US consumer price index, yielding a base case
value of $49.72. To allow for community publicity, we added
$5. (Input values are reported in Table 1.)
Our cost structure assumes zero additional training and
physical infrastructure development costs in connection with
high levels of circumcision coverage and does not assume that
any economies of scale will be realized. We varied the cost per
MC by 650% to reflect these potential efficiencies or
inefficiencies of scale-up.
In the OF trial, no death was attributable to MC, and the
frequency of adverse events during surgery and within one
month postoperatively was 3.8% (60/1,568). These included
pain, excessive bleeding, infection, damage to the penis,
swelling or hematoma, anesthesia-related events, excessive
skin removed, insufficient skin removed, delayed wound
healing, problems with urinating, and problems with appear-
ance. Of these 60 adverse events, 58 were cured by a
supplementary visit to a doctor and two necessitated a short
hospitalization (2 d). The cost of the doctor visit including
medication was estimated as $13.04, and the cost per hospital
day at $167.20 [39]. These estimates are based on resources
required for services to HIV-infected patients assuming 71%
are served at a district-level hospital and 29% in a tertiary
care facility, and thus are likely to overestimate the costs
required for MC patients. At the end of follow-up, there were
11/1,185 (0.9%) adverse outcomes (problems with urinating,
dissatisfaction with the appearance of the penis, mild or
moderate erectile dysfunction, and torsion of penis). None of
them led to permanent damage but they necessitated an
outpatient visit to a doctor. Thus, the overall cost of adverse
events standardized for 1,000 individuals was: 1,000 3 ([58/
1,568 3 13.04] þ [2/1,568 3 2 3 167.2] þ [0.9% 313.04]) ¼
$1,030.
The adverse events in the OF trial were immediately
reported by general practitioners and were also reported by
the participants and collated by a nurse at follow-up visits
months after circumcision. Since this recall-based reporting
may lead to underestimates of the rate of adverse events, we
conducted a sensitivity analysis using three times this rate.
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These data may also overestimate adverse events attributable
to MC (i.e., they are unadjusted for events in controls);
however, we conservatively do not examine a reduced rate.
The lifetime cost of HIV treatment is based on a recent
study in South Africa [39]. This study, which used data from
pilot clinics for a prospective disease state model, estimated a
lifetime discounted cost of $11,948 with ART and $3,793
without ART. We conservatively use $8,000 as the base case
value, implying 50% access to ongoing ART, and explore a
wide range from $4,000 to $12,000.
Effectiveness
We define effectiveness as the number of HIV infections
prevented per 1,000 newly circumcised men over a specified
number of years (base case ¼ 20). We calculate this
effectiveness as the product of the number of HIV suscep-
tibles, the HIV incidence rate, the protective effect of MC
(adjusted for risk compensation), the projection period (in
years), and an epidemic multiplier. This can be represented
as: Effectiveness ¼ number newly circumcised 3 (1  HIV
prevalence) 3 incidence rate 3 net protective effect 3
projection period 3 epidemic multiplier, where net protec-
tive effect ¼ [1  (1  protective effect) 3 (1 þ risk
compensation)].
Each element of the equation is explained below.
The number newly circumcised is defined as the number of
men in the cohort that will receive circumcision (set at 1,000).
This includes men who are HIV-infected and uninfected.
The factor (1  HIV prevalence) limits the analysis of
effectiveness to those who are initially HIV-uninfected. The
prevalence in adult men in Gauteng Province is 25.6% and we
use this value [40]. Limiting the direct application of MC
effectiveness to HIV acquisition among male susceptibles is
conservative, but appropriately so given the HIV incidence
outcome examined by the OF trial and the biological
evidence. Those who are HIV-positive when circumcised do
not contribute to effectiveness but do contribute to the cost.
HIV incidence rate represents the HIV acquisition risk that
is lowered by MC. In a steady-state epidemic, an incidence of
0.038 is required to maintain an HIV prevalence of 25.6%
(calculation available on request). For the base case analysis,
we vary prevalence from 0.2 to 0.3 (corresponding to
incidence of 2.8 per 100 person years and 4.8 per 100 person
years, respectively). To examine results in a range of epidemic
settings as well as circumcision for 18–24 year olds, we varied
the prevalence down to 10% (incidence 1.4 per 100 person
years).
The expression for net protective effect integrates the
competing effects of biological protection by MC and
potential risk compensation. The expression yields a net
protection by combining the estimated RR of HIV acquisition
due to each factor. If MC reduces the risk of acquisition by
60%, then the new RR of acquisition, absent behavior change,
is 0.4 (i.e., 1.0–0.6). If risk compensation causes risk behavior
to rise by 20%, this increases the RR of acquisition
approximately linearly when incidence per time period is
low [41], i.e., RR ¼ 1.2. The combined effect of these two
factors on RR is multiplicative, i.e., 0.4 3 1.2 ¼ 0.48.
Subtracting this RR from 1.0 yields the net protective effect
(e.g., 0.52).
The protective effect found in the OF trial was 0.60, from a
proportional hazards model. Statistically controlling for the
increase in sexual risk behaviors in the intervention group
had a minor impact on the estimated protective effect. We
assume that the effect found in the trial is applicable to all
men, and is causal without specifying a mechanism of action.
We use 0.6 as the reduction in transmissibility, and separately
model risk behavior increases due to risk compensation
(defined below).
Risk compensation—i.e., increases in risk behavior pre-
cipitated by intervention-induced sense of reduced risk—is a
major concern for any HIV-related prevention innovation
[42]. A study in Kisumu (Kenya) showed that the sexual
behavior of circumcised men was not different from that of
uncircumcised men [43]. In contrast, a study in Uganda
showed that circumcised men had a higher risk profile than
uncircumcised men [44].
The MC RCT in OF found an 18% increase in the mean
Table 1. Input Values and Cost-Effectiveness Analysis of Male Circumcision
Input Category Input Base Case Value Range Sources
Costs Cost per male circumcision $54.72 $27–$82 [13] (OF trial)
Number of male circumcisions performed 1,000 NA Assumption
Cost per 1,000 male circumcisions $5,472 $2,700–$8,200 Calculated
Frequency of short-term adverse events (outpatient) 0.037 0.017–0.057 [13] (OF trial)
Cost per short-term mild adverse event (outpatient) $13 $6–$20 [39]
Frequency of short-term adverse events (inpatient) 0.0013 0.0005–0.002 [13] (OF trial)
Cost per short-term adverse event (inpatient) $334 $174–$494 [39]
Frequency of long-term adverse events 0.0093 0.005–0.014 [13] (OF trial)
Cost per long-term adverse event $13 $6–$20 [39]
Lifetime medical care cost of HIV/AIDS $8,000 $4,000–$12,000 [39]
Effectiveness Proportion HIV-uninfected 0.744 0.7–0.8 [40]
HIV incidence rate 0.038 0.028–0.048 Calculated
Protective effect 0.6 0.34–0.77 [13] (OF trial)
Risk compensation impact on protective effect (relative) 0.25 0.0–0.5 [13,43,44]
Years 20 10 Assumption
Multiplier due to epidemic effects 1.5 1.0–2.0 See Protocol S1
NA, not available.
doi:10.1371/journal.pmed.0030517.t001
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number of sexual contacts in intervention subjects versus
controls. We assumed that risk compensation might be higher
in a nonresearch program scale-up, and used a 25% increase
in the frequency of risk behavior as the base case, varied in
sensitivity analyses, from 0% to 50%. The 25% increase
corresponds to a net protective effect of 0.50.
A projection period of 20 years was chosen for the base
case analysis. This duration captures the persistent protective
effect of male circumcision as well as delayed epidemic
effects.
The epidemic multiplier was used to portray the effect of
three factors that cause infections prevented to deviate from
the simple product of HIA in the first year and the number of
years projected. The first factor is that HIV infections
prevented in men with circumcisions will lead to HIA in
female partners in the community. In stable epidemics in a
population with a negligible growth rate, each infected
individual is responsible for an average of one HIV infection
transmitted to others. Thus, if all other factors are constant,
each infection prevented in HIV-negative men by MC (direct
impact) might be expected on average to lead to one
additional infection prevented in female partners. Because
we consider a time period of 20 years in the base case, HIA
late in that period (e.g., at year 15) would avert less than one
infection.
A second factor that would enhance the benefits of MC is
that, when a substantial number of men are circumcised and
there is an indirect reduction in infections in women (as
above), the lower HIV prevalence among women will further
decrease risk to men. This will lead the epidemic to a new
steady state with decreased prevalence and thus incidence
among both women and men. The magnitude of this factor is
best estimated with a time-dependent epidemic model.
However, since it is one level of transmission further from
the intervention (and thus delayed) and requires the slow
decrease in HIV prevalence, we expect a somewhat smaller
effect in the 20-year time frame.
Finally, the lower HIV prevalence in women resulting from
the first infections averted by MC reduces the later incidence
rate in susceptible men and hence the benefits of subsequent
MC. This effect is also likely to be modest, as it operates
through lower prevalence in women. It may vary with scale:
an MC program with higher coverage yields a sharper drop in
epidemic severity as compared with severity when the initial
circumcisions occurred. We consider this factor as part of the
overall epidemic multiplier and also separately.
In order to estimate the combined effect of these three
factors, and to conduct sensitivity analyses, we adapted a
simple dynamic epidemic modeling approach reported
previously (described in Protocol S1). Overall, the ‘‘epidemic
multiplier’’ representing all three factors was estimated as
1.53; we use 1.5 (range 1.0–2.0). While this simple model
cannot capture the full range of epidemic dynamics as
reported previously [14], it does permit a more accurate
translation of protective effect in the RCT to epidemic
benefit.
To compare effectiveness in preventing HIV to the health
losses associated with adverse events, we calculated net
DALYs. We estimated net DALYs by subtracting the increase
in DALYs due to adverse events from the reduction in DALYs
due to HIA. We calculated the reduction in DALYs for HIV by
multiplying HIA by previously reported discounted DALY
changes with ART (ten DALYs) and without (21 DALYs),
assuming 50% on ART [45]. For increases in DALYs, we
estimated the frequency and duration of adverse events from
the OF RCT. We were explicitly pessimistic about the
disutility of adverse events, assuming health state utility ¼ 0
for most adverse events for their full duration. We used this
approach because of the difficulty of obtaining utilities for
these health states in this setting, and because even
pessimistic assumptions yielded DALY increases from adverse
events nearly two orders of magnitude smaller than DALY
reductions from averted HIV infections. Detailed assump-
tions are available on request from JGK. We used the
productivity weight for 25-year-olds (1.49) [46,47].
Results
Base Case Results
The cost of providing 1,000 MCs is estimated as $54,724 for
the procedure and community publicity, and an additional
$1,030 for management of adverse events. The total is
$55,754. Base case results are presented in Table 2.
We estimate that over 20 years, the 1,000 circumcisions
would avert 427 adult HIV infections (308 discounted to the
present at 3%). This represents the combined effect of
protection from the MC, 25% behavioral risk compensation,
and a 1.5 epidemic multiplier reflecting secondary effects. An
estimated two-thirds of infections are averted in men, and
one-third in women.
We estimate that the HIA represent a reduction of 4.77
DALYs per MC (0.308 HIA per MC 3 15.5 fewer DALYs per
HIA). We pessimistically estimate a gain of 0.168 DALYs due
to adverse events per MC, equal to 3.5% of DALYs averted.
Thus, the net DALYs reduction per MC is 4.61, or 4,606 per
1,000 MCs.
The cost per HIA is estimated at $181 ($55,754/308). When
adjusted for averted lifetime HIV medical costs of $8,000, the
net savings for 1,000 MCs is $2,411,427 ($2,411 per MC).
Sensitivity Analyses
The results below reflect variation in input values as
reported in Table 1.
One-way sensitivity analyses. The cost per HIA, unadjusted
for medical cost savings, is most sensitive to the estimated
protective effect of MC, with values declining from $393 to
Table 2. Program Cost, HIA, and Cost-Effectiveness of Male
Circumcision
Category Element Value
Program cost Cost of male circumcision $54,724
Cost of adverse events $1,030
Total cost $55,754
HIA Undiscounted 426.7
Discounted 308.4
Cost-effectiveness Cost per HIA (unadjusted
for averted medical care costs)
$181
Net cost, adjusted for
averted medical care costs,
for 1,000 MC (savings)
($2,411,427)
doi:10.1371/journal.pmed.0030517.t002
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$129 as protective effect increases from 0.34 to 0.77 (Figure
1). The cost of the MC procedure is the factor with the second
largest effect on this outcome. Cost per case averted ranged
from $110 to $250 as the cost of MC ranges from $27 to $82.
Results are similarly sensitive to the multiplier due to
epidemic effects, declining from $245 to $143 as the multi-
plier increases from 1.0 to 2.0. Results are relatively
insensitive to variations in the value of other inputs,
including HIV prevalence for this population (HIV preva-
lence values representing different populations are consid-
ered below under ‘‘Scenarios’’). Results are extremely
insensitive to the frequency of short-term adverse events,
i.e., a 10-fold increase in the incidence of short-term adverse
events decreases program net savings by 0.05%.
The factor with the greatest effect on overall costs adjusted
for averted HIV medical expenditures was the protective
effect of MC (Figure 2). Across the range of values we
examined, 0.34–0.77, the net savings ranged from $1.1 million
to $3.4 million. Other factors with large effects on results
were the lifetime medical cost of HIV as a function of
proportion on ART (savings of $1.4 million to $3.4 million)
and the epidemic multiplier ($1.8 million to $3.1 million). An
MC program breaks even or generates net costs only if the
protective effect of MC is 0.21 or lower.
We examined the effect of a key method. If the time frame
were ten years, HIA would drop to 155, with net savings of
$1.18 million. A time frame of 50 years would increase HIA
and net savings. We did not quantify these values due to
limitations in our model’s ability to account for population
turnover, as well as large uncertainty regarding epidemic
projections and prevention and treatment technologies.
Three-way sensitivity analysis. Table 3 shows the effect on
the cost per HIA when varying the protective effect of MC, its
cost, and the epidemic multiplier. The least attractive
outcome is obtained when the protective effect is near the
low end of its range, 40%, program costs are at the high end,
$100 per MC performed, and the epidemic multiplier is 1.0.
In this pessimistic situation, the cost per HIA reaches $1,031,
Figure 1. One-Way Sensitivity Analyses of the Cost per HIA Unadjusted for Anticipated Averted HIV Treatment Expenditures
For each of the varied input values, results correspond to the ranges shown in Table 1. The 50th percentil corresponds with the base case. Similarly, the
first and 99th percentiles approximate the low and high end of the ranges shown in Table 1, respectively. For example, the high-end cost per male
circumcision is $82 (Table 1), which corresponds to the 99th percentile of the range, or $250 per HIA. This figure indicates that the unadjusted cost per
HIA is most sensitive to uncertainty in the MC protective effect, cost per MC, and epidemic multiplier.
doi:10.1371/journal.pmed.0030517.g001
Figure 2. One-Way Sensitivity Analyses of the Cost of 1,000 Male Circumcisions after Deducting Averted HIV Treatment Costs
For each of the varied input values, results shown correspond to the ranges shown in Table 1. The 50th percentile corresponds with the base case.
Similarly, the first and 99th percentiles approximate the low and high end of the ranges shown in Table 1 respectively. Parentheses indicate savings.
This figure indicates that the cost per HIA adjusted for averted HIV treatment costs is most sensitive to uncertainty in the MC protective effect, lifetime
medical care cost for HIV/AIDS, and epidemic multiplier.
doi:10.1371/journal.pmed.0030517.g002
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with net savings reduced to $716,000. At the other extreme, if
the protective effect reached 70%, MC costs dropped to $30,
and the epidemic multiplier was 2.0, the cost per HIA would
be $70, and the net savings would reach $4.1 million.
Threshold analyses. In order for the MC program to have a
net cost of zero for the base case epidemic setting, the
protective effect would need to drop by two-thirds to 20.9%
or the cost would need to increase 45-fold to $2,466.
In order for the MC to result in stable HIV incidence (no
HIA), and using the best estimate of protective effect of 0.60,
risk compensation would have to be 1.5 (i.e., 150% increase in
risk behaviors). Assuming the worst case protective effect of
0.34, for stable HIV incidence the risk compensation would
have to be 0.52 (as compared with a best estimate of 0.25).
Multivariate sensitivity analysis. The multivariate Monte
Carlo simulation showed that the number of discounted HIA
over 20 years for 1,000 clients ranged from 130 to 486 at the
95% confidence level, and from 189 to 428 at the 80%
confidence level. The unadjusted cost per case averted ranged
from $95–$427 and from $117–$306 at the 95% and 80%
confidence levels, respectively. Program cost adjusted for
averted medical care costs ranged from savings of $0.9 million
to $4.3 million at the 95% CI, and savings of $1.3 million to
$3.6 million at the 80% confidence level.
When we repeated this simulation with uniform distribu-
tions for model input values, the resulting ranges in values of
outcomes were wider but the finding of net savings remained.
The number of discounted HIA was 99–574 (95% CI) and
151–475 (80% CI). The unadjusted cost per case averted was
$71–$603 (95% CI) and $97–$390 (80% CI). Net savings
ranged from $0.6 million to $5.4 million for the 95% and
80% confidence levels, respectively.
Scenario sensitivity analysis. With an HIV prevalence of
8.4% and incidence of 0.01 per susceptible per year (i.e., a less
severe steady state), the cost per HIA increases nearly 3-fold
to $551 (80% CI $344–$1,071) and net savings are $753,000
(80% CI $330,000–$1.2 million). With prevalence still at
25.6% but incidence decreased to 0.01 per susceptible per
year (i.e., a rapidly waning epidemic due to reduced risk
behavior), there are 48 infections averted, at net savings of
$264,246.
Performing MC in younger men (18–24 years old) may
substantially improve cost-effectiveness, by averting the rise
in prevalence that occurs with ongoing risk. With a starting
HIV prevalence of 10% and incidence of 0.021 (as observed in
the OF trial), our model predicts one-third more infections
prevented over 20 years than with MC in all adult men. The
cost per HIA would be $135.
If MC is performed in younger men after all adult men have
been circumcised, cost-effectiveness becomes less favorable
than the base case results. Assuming HIV prevalence and
incidence of 8.5% and 0.015, respectively, our model predicts
20% fewer infections averted. The cost per infection averted
would be $228.
The base case represents full coverage with MC. That is, all
men eligible for circumcision receive it. If coverage were low
(10%) despite recruitment at a cost of $5 per eligible, the cost
would be $100 per MC performed. For 1,000 eligibles, there
would be 100 MC, 33 discounted HIA, and net savings of
$253,897.
The effect of coverage on effectiveness is small. When
coverage (or uptake) is lowered by half as compared with the
base case, the number of HIA per 1,000 MC increases by 1%.
This effect reflects the balance of two forces. An MC program
with high coverage yields a drop in epidemic severity, so that
the residual HIV incidence affected by the last MC is
substantially less than the HIV incidence affected by the first
MC. However, specified drops in HIV incidence yield
proportionally larger drops in prevalence in lower incidence
ranges than in higher incidence ranges. The balance of these
forces is the net scale effect. At different starting levels of
HIV prevalence and incidence, we found a scale effect
favoring smaller programs of 1%–10%.
Discussion
Previous studies have demonstrated that MC reduces HIV
transmission. The present analysis demonstrates that MC can
lower health system costs. This is due to moderate imple-
mentation costs, high and durable protective effects, and the
resulting averted HIV care costs. This finding is robust across
a wide range of plausible parameter input values for South
Africa, including lower effectiveness, higher costs, and lower
HIV incidence.
This analysis also suggests that MC, at $181 in program cost
per HIV infection prevented and cost saving when adjusted
for averted medical costs, is amongst the most economically
efficient of HIV prevention strategies in sub-Saharan Africa.
The cost per HIA has been estimated at $68–$79 for peer
education for sex workers, $58 for mass media, $10–$2,188
for condom distribution, $393–$482 for voluntary counseling
and testing, $20–$2,198 for antiretroviral drugs to prevent
mother-to-child transmission, $271–$514 for treatment of
other sexually transmitted infection, and $7,288–$13,326 for
school-based education. As noted below, the latter three
interventions have mixed data on effectiveness, making the
cost-effectiveness estimates less certain. MC is as econom-
ically favorable as inexpensive medical interventions for HIV,
Table 3. Three-Way Sensitivity Analysis
Multiplier Value Protective
Effect
Cost per HIA ($) in
Three Unit Cost Groups
Unit
Cost $30
Unit
Cost $50
Unit
Cost $100
Epidemic multiplier ¼ 1.0 40% 350 545 1,031
50% 234 363 688
60% 175 271 516
70% 140 218 413
Epidemic multiplier ¼ 1.5 40% 234 363 688
50% 156 242 458
60% 117 181a 344
70% 93 145 275
Epidemic multiplier ¼ 2.0 40% 175 273 516
50% 117 182 344
60% 88 136 258
70% 70 109 206
Sensitivity of cost per HIA to unit cost, protective effect, and epidemic multiplier is shown
per MC. Variation of the cost per case of HIA (unadjusted for averted lifetime HIV medical
costs), according to selected combinations of values for the protective effect, cost of male
circumcision, and epidemic multiplier. All other inputs retain base case values as shown in
Table 1.
aThe base case value is $181 per HIA.
doi:10.1371/journal.pmed.0030517.t003
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such as INH prophylaxis at $703 per fatal case averted or cost
saving if averted secondary TB cases are included [19,20,48]
and cotrimoxazole prophylaxis, which is also likely to be cost
saving [49,50].
Other infectious disease interventions that are considered
economically attractive in sub-Saharan Africa according to
the World Bank’s Disease Control Priorities in Developing Countries
[51] have costs per averted DALY ranging from $2–$400.
Standard childhood immunization costs $1–$5 per DALY.
Malaria interventions including insecticide treated bed nets
and residual household spraying cost $2–$24 per DALY.
Improved quality and coverage of maternal and neonatal care
are less cost-effective, $82–$409 per DALY [52]. We assume
that these cost-effectiveness estimates were adjusted for
medical care costs, suggesting net costs rather than net
savings as with MC.
The evidence of the effectiveness of MC is consistent but
not yet definitive. Results from the OF trial, consistent with a
meta-analysis of observational studies, show a 60% protective
effect. However, a limitation of this study is relying on only
one clinical trial; two further trials are pending. Some other
prevention interventions, though having an attractive cost
per HIA in favorable circumstances, have often been found to
lack evidence of effectiveness. This is true of mass media
programs, school programs, and may also pertain to STI
treatment [6,51].
Acceptability of MC remains a significant concern, due to
strong cultural values regarding circumcision status and
practices. Coercion should not be employed to overcome
reluctance to obtain MC. Yet, high levels of acceptability of
MC have been demonstrated in various African settings
including Botswana, Kenya, Zimbabwe, and South Africa,
where acceptability rates of 60%–70% were reported [53–56].
A community cross-sectional survey conducted in South
Africa suggests that over 70% of noncircumcised men would
elect circumcision if it protected against STIs. Two-thirds of
the African population is already circumcised, including
many African countries where all are circumcised, and where
there is only a minority of Muslims (Benin, Cameroon,
Democratic Republic of the Congo). Historical data suggest
that MC can be increased (South Korea from 0% in 1900 to
about 60% today) or decreased (Zulu were circumcised 200
years ago but not today) [57,58].
In some settings, low acceptability will reduce uptake.
However, even if due to limited acceptability MC occupies a
smaller HIV prevention niche, its high cost-effectiveness still
argues for implementation of appropriately scaled programs.
This may be especially true if acceptability evolves over time:
‘‘early adopters’’ pave the way for others later [59].
In the South African survey, 29% of circumcised and 22%
of noncircumcised men believed that circumcision protects
against HIV and other STIs [53]. A less encouraging result
from this survey is that 30% and 18%, of circumcised and
uncircumcised men respectively, believed that circumcision
would permit them safely to have sex with multiple partners.
Furthermore, circumcised men were more likely to report
many lifetime partners than were their uncircumcised peers.
These data underline the importance of further research
regarding the educational campaigns and specific messages
that would encourage participation while minimizing risk
compensation.
These concerns also argue for capitalizing on the com-
plementarities between MC and behaviorally based HIV
prevention modalities such as condom promotion and
counseling for partner reduction and other risk reduction.
MC can serve as a portal for other male reproductive health
services, including HIV prevention, which clients might
otherwise not access. Even if not fully integrated with broader
prevention services, MC facilities could routinely refer
patients to programs that provide these services. For HIV-
infected MC candidates this could also include referral for
ART.
Complementarities are also present in the types of
personnel required by MC programs. MC requires trained
medical practitioners, but does not compete for the scarce
supply of trained counselors, health educators, and field
personnel who are the backbone of other HIV prevention
and treatment modalities. Combined with the willingness in
the OF RCT of general practitioners to perform MC at a
reasonable price, these labor complementarities should
enhance the feasibility of conducting an MC program without
slowing other HIV activities. We are now planning research
on the feasibility of scale-up.
Generalization of HIV prevention effectiveness and cost-
effectiveness research is a universal concern. One issue is the
effectiveness of prevention technology in other geographic
settings, with different beliefs and behaviors. We believe that
MC protective effect, based on biological rather than
behavioral change, is more valid to generalize to other
settings than are most HIV prevention strategies. For
economic analyses, adjustment to local cost levels is neces-
sary. Another issue is extrapolation from short-term trials to
long-term effects. Again, we believe that the biological nature
of MC fosters higher confidence in generalization. Risk
compensation is an important phenomenon not reliably
generalized from a short-term trial to other settings or time
frames, and thus worthy of ongoing evaluation.
We believe that this analysis for South Africa applies to
other sub-Saharan settings. The epidemic situation in South
Africa (heterosexual spread, high HIV prevalence, low MC
prevalence) is similar to most southern African countries
(e.g., Lesotho, Zimbabwe, Swaziland, Botswana, Zambia).
Although more men in the other sub-Saharan locations are
circumcised, our economic findings are similar for large and
incremental MC efforts. Our MC cost data are consistent with
data from Kenya, and our sensitivity analyses confirm that
MC is cost saving for a wide range of economic and
epidemiologic conditions. We are therefore confident that
our findings are relevant beyond South Africa.
We cannot be certain if trial-derived parameter values will
differ from those found in actual practice. Some of those
most subject to variability, such as risk compensation and the
frequency of severe adverse events, have substantial influence
on the cost-effectiveness results. High-risk compensation in
the context of lower bound MC protective effect could even
lead to the loss of HIV prevention benefit. However, the
range of parameter values explored in the sensitivity analyses,
including some that appear to be extremely pessimistic,
provide substantial reassurance that MC can be effective and
cost saving. Research on operating programs will permit
refinement of key parameter values.
Unit costs may decline and cost-effectiveness rise following
wide intervention adoption. This could arise from the usual
economies attendant upon large volumes. In addition, it is
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possible that lower cost nonmedical doctor paramedics,
nurses, and traditional circumcisers could be trained to
perform MCs safely and successfully. It is also possible that
benefits are greater than estimated here. This could occur, for
example, if MC were found to confer protection on women in
addition to the circumcised men. Our estimate did not take
into account the prevention of HIV infection among new-
borns due to the indirect protective effect on adult women,
which would also tend to lower cost-effectiveness.
By improving clinical outcomes or prevention, public
health programs sometimes reduce future medical care costs.
However, these medical care cost savings are often realized in
a different budget. When the entity charged with funding the
program does not realize the savings, it may be less motivated
to implement a program of prevention than it would be if
these savings accrued to its own budget. MC and HIV care are
both in the medical budget rather than the public health
budget. For this reason, decision makers considering imple-
mentation of an MC initiative would not only incur the costs
of such a program but would also make savings in future HIV/
AIDS care. On a cash-flow basis, the project should thus be
attractive to the administering agency, yielding a stream of
net savings starting approximately 6–8 years after implemen-
tation, when most MC clients would otherwise have started
consuming medical care costs for HIV/AIDS treatment. This
alignment of budgetary costs and benefits could thus raise the
political and administrative acceptability of this proposal.
If adopted in the context of high-quality medical services
and appropriate community and individually oriented health
education programs, MC could contribute significantly to
reducing HIV transmission in Southern Africa. Findings from
this study suggest that MC could be highly cost-effective or
could save health system funds. Botswana, Lesotho, Malawi,
Mozambique, Namibia, South Africa, Swaziland, Uganda,
Zambia, and Zimbabwe combine low MC prevalence with
high HIV prevalence. These countries are therefore poten-
tially high-priority candidates for implementation.
Supporting Information
Protocol S1. Cost-Effectiveness of Male Circumcision for HIV
Prevention in a South African Setting
Found at: doi:10.1371/journal.pmed.0030517.sd001 (32 KB DOC).
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Editors’ Summary
Background. Preventing the spread of HIV is an enormous challenge of
great importance worldwide. In 2005, HIV/AIDS was responsible for
around 3 million deaths, of which approximately one-third were in sub-
Saharan Africa. HIV is spread from one person to another in three main
ways: through unprotected sex; through contaminated blood or blood
products (for example when shared needles are used); and from mother
to child (during pregnancy, labor, and breastfeeding). Many strategies for
preventing HIV focus on reducing risky behaviors. For example, condoms
used correctly are effective at preventing HIV infection, and many
countries now aim to promote condom use, together with other
approaches that will reduce the risk of getting HIV. However, it is unlikely
that strategies involving large-scale changes in behavior will ever be
completely effective. Recently, much attention has focused on the
possibility that circumcision might provide men with some protection
against getting HIV. The results of a trial carried out in South Africa, the
ANRS 1265 trial (published in PLoS Medicine in October 2005) seem to
support this theory, and additional trials are being carried out in Kenya
and Uganda. The results from these further trials will help determine
whether, and to what extent, the effect of circumcision seen in the South
African trial is true more generally.
Why Was This Study Done? The investigators who had carried out the
South African circumcision trial wanted to find out how the economic
aspects of this prevention strategy would compare with other strategies
for prevention of HIV. Specifically, they wanted to know how much male
circumcision would cost overall, per HIV infection prevented, as
compared with the cost of other strategies. They also wanted to
understand whether circumcision would be ‘‘cost-saving.’’ In other
words, would the cost of performing the operation (together with the
cost of treating any adverse effects suffered by the men who were
circumcised) be offset by the costs of treatment for HIV infections that
the intervention prevented? Getting this information is crucial before
health policy makers can decide what strategies for preventing HIV are
most appropriate for their country.
What Did the Researchers Do and Find? In this study, the researchers
carried out a set of mathematical calculations, using the results from the
ANRS 1265 trial, together with some other data and background
assumptions. Their model was based on a hypothetical group of 1,000
men, all of whom would be circumcised. The researchers calculated that
in such a hypothetical group, the cost of providing male circumcision,
per HIV infection prevented, would be around $180. Overall, this
procedure seemed to be cost-saving when the cost of HIV treatment was
also factored in; around $2.4 million would be saved for the 1,000 men
circumcised.
What Do These Findings Mean? These results suggest that, assuming
the results of the South African trial are generally true, male circumcision
would reduce the cost of health care in South Africa, mainly through
savings on the cost of HIV treatment. The overall cost of male
circumcision, per HIV infection prevented, is reasonable as compared
to the costs of other strategies for prevention of HIV. There would also
be implications for HIV prevention programs in other African countries.
However, these estimates are based on the data from one trial only. The
World Health Organization does not currently recommend the promo-
tion of male circumcision for prevention of HIV. Meanwhile, proven
strategies for preventing HIV exist, and more information is available
from the links below.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030517.
 The World Health Organization has an HIV/AIDS program site
providing comprehensive information on the HIV/AIDS epidemic
worldwide
 General information and resources from the US Centers for Disease
Control and Prevention on preventing HIV/AIDS
 Fact sheet from the Joint United Nations Programme on HIV/AIDS
about male circumcision and HIV
 Results of the ANRS 1265 Trial evaluating male circumcision for HIV
prevention were published in PLoS Medicine in October 2005; two
related ‘‘Perspective’’ articles were also published in the same issue by
Nandi Siegfried and Peter Cleaton-Jones
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